Dr. Qunling Zhang 张群岭
Chief Physician
Hematologic Oncology, Fudan University Shanghai Cancer Center, Shanghai
Public profile Compiled from public listings and PubMed. We do not work directly with this doctor, but we can find a specialist in this field to review your case.
Get a specialist opinionClinical focus: Comprehensive treatment of malignant lymphoma, with a focus on peripheral T-cell lymphoma, diffuse large B-cell lymphoma, and indolent B-cell lymphoma.
Dr. Zhang holds a PhD from Shanghai Jiao Tong University School of Medicine. After training at Xi'an Jiaotong University, Dr. Zhang completed a one-year fellowship at Roswell Park Cancer Center (2014–2015) and worked at the National Medical Products Administration New Drug Review Center (2016–2017). Research focuses on peripheral T-cell lymphoma, with findings published in Blood and Leukemia.
Name order: in Chinese the family name comes first (Zhang Qunling). Papers usually list the name as Qunling Zhang or Zhang Q.
Selected publications
68 papers on PubMed matched by name and affiliation; 12 as first or senior author since 2016. Most recent first- or senior-author papers:
- Blood Cancer J, 2026 (first author): Correction: Zanubrutinib combined with R-CHOP in previously untreated diffuse large B-cell lymphoma with specific gene alteration: a phase II study. PubMed 42988811
- Asia Pac J Clin Oncol, 2026 (senior author): Prognostic Significance of Deubiquitinase OTUD7B in NK/T-Cell Lymphoma. PubMed 41283788
- Hematol Oncol, 2026 (senior author): Clinical Impact of BTK Inhibitor Exposure in LymphGen-Defined MCD Diffuse Large B-Cell Lymphoma. PubMed 42479904
- Blood Cancer J, 2026 (first author): Zanubrutinib combined with R-CHOP in previously untreated diffuse large B-cell lymphoma with specific gene alteration: a phase II study. PubMed 42386710
- Front Oncol, 2026 (senior author): Elevated FGR protein expression identifies a high-risk subset of diffuse large B-cell lymphoma and a potential therapeutic target. PubMed 42078811
- Asia Pac J Clin Oncol, 2023 (senior author): Serum miR-146a level is a potential biomarker in predicting the outcome of diffuse large B-cell lymphoma. PubMed 36540006
- Int J Hematol, 2022 (senior author): Hexokinase II expression as a prognostic marker in diffuse large B-cell lymphoma: pre- and post-rituximab era. PubMed 35536508
- J Cancer, 2022 (senior author): Deubiquitinase OTUD7B is a potential prognostic biomarker in diffuse large B-cell lymphoma. PubMed 35154465
See the full PubMed search. Automatic matching can miss papers or include a namesake at the same hospital.
This profile has not been reviewed by the doctor. How we build this directory.
Want a specialist to review your case?
Send your records. We find a specialist in this field who can review your case and write a treatment plan with a cost estimate.
Get a specialist opinion